Abstract Title
Developing and accelerating new and efficacious animal influenza vaccines
Abstract
Vaccination is a key measure to prevent and control influenza in animals and mitigate the risk to humans. Vaccine efficacy is constantly challenged by high genetic and geographic dynamic of influenza viruses. New technology vaccines can better overcome this challenge than conventional inactivated vaccines. The global COVID-19 vaccination with RNA vaccines has shown the potential of this technology with quick vaccine development and production, thus optimal for emerging epizootic pathogens. A poultry H5 vaccine based on self-amplifying RNA technology has already been massively used since 2024 in French duck production.
A Ceva project (BioFluRNA) is aimed at establishing a process for quick and reliable development of poultry and swine influenza RNA vaccines. Such a process integrates real-time surveillance, virological data, machine-learning algorithms, workflows for sequence design, decision criteria and Standard Operating Procedures. The project also includes tools development and trials for sequence design of broadly protective vaccines, for measurement of the full immune response, evaluation of their efficacy, and modeling for optimized vaccination strategies. The project implementation has so far confirmed the feasibility of linking field activities with vaccine constructs based on field and sequence information. Such vaccines could be developed within less than three months; millions of doses could be generated within a few weeks. The registration/authorization process of such emergency vaccines needs to be as short as possible in emergency situations. This project is co-funded by Ceva and the French public 2030 investment plan aimed at funding research and innovation to prevent and respond to Emerging Infectious Diseases.
A Ceva project (BioFluRNA) is aimed at establishing a process for quick and reliable development of poultry and swine influenza RNA vaccines. Such a process integrates real-time surveillance, virological data, machine-learning algorithms, workflows for sequence design, decision criteria and Standard Operating Procedures. The project also includes tools development and trials for sequence design of broadly protective vaccines, for measurement of the full immune response, evaluation of their efficacy, and modeling for optimized vaccination strategies. The project implementation has so far confirmed the feasibility of linking field activities with vaccine constructs based on field and sequence information. Such vaccines could be developed within less than three months; millions of doses could be generated within a few weeks. The registration/authorization process of such emergency vaccines needs to be as short as possible in emergency situations. This project is co-funded by Ceva and the French public 2030 investment plan aimed at funding research and innovation to prevent and respond to Emerging Infectious Diseases.
Co-Author(s)
Gwenaëlle Dauphin1, Christophe Cazaban1, John El Attrache 1, Kurt Kamrud2, Thomas Lewinner1
1Ceva Animal Health, Corporate, Libourne, France; 2Ceva Animal Health, Lenexa, United States.
Abstract Category
Diagnostics, vaccination, or other mitigation strategies for poultry and wildlife